NCT02366819 2026-03-30
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
University of Chicago
Phase 4 Suspended
Clinical Trials
8 trialsNCT07094893 2026-01-14
ARIEL-ENGIC
Gruppo Oncologico del Nord-Ovest
Phase 4 Not yet recruiting
NCT01271582 2019-01-29
Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients
Asan Medical Center
Phase 4 Unknown
NCT02348450 2016-12-05
Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer
Guangdong Association of Clinical Trials
Phase 4 Unknown
NCT02401971 2015-03-30
ITAGC
Zhengzhou University
Phase 4 Unknown
NCT00808184 2012-11-01
Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype
National University Hospital, Singapore
Phase 4 Completed
NCT00138060 2010-07-20
Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants
Institut de Recherche Clinique sur les Cancers et le Sang
Phase 4 Completed
NCT00220168 2009-12-16
Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours
Royal Marsden NHS Foundation Trust
Phase 4 Completed